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Mutation of mitochondrial DNA (mtDNA) G13513A, encoding the ND5 subunit of res-
piratory chain complex I, can cause mitochondrial encephalopathy with lactic aci-
dosis and stroke-like episodes (MELAS) and Leigh syndrome. Wolff-Parkinson-White 
(WPW) syndrome and optic atrophy were reported in a high proportion of patients 
with this mutation. We report an 18-month-old girl, with an 11-month history of psy-
chomotor regression who was diagnosed with WPW syndrome and hypertrophic car-
diomyopathy, in association with Leigh syndrome. Supplementation with coenzyme 
Q10, thiamine and carnitine prevented further regression in gross motor function but 
the patient’s heart function deteriorated and dilated cardiomyopathy developed 11 
months later. She was found to have a mutation of mtDNA G13513A. We suggest that 
mtDNA G13513A mutation is an important factor in patients with Leigh syndrome 
associated with WPW syndrome and/or optic atrophy, and serial heart function 
monitoring by echocardiography is recommended in this group of patients.
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Leigh syndrome is a progressive neurodegenerative 
disease, which usually affects infants, but has also 
been described in adults. It is characterized by bi-
laterally symmetrical lesions in the brainstem and/
or basal ganglia.1 It is associated with defects in 
mitochondrial energy production. Many associated 
biochemical and molecular defects have previously 
been reported in the literature, including defects in 
pyruvate dehydrogenase complex, complex I (NADH 
ubiquinone reductase), complex II (succinate ubi-
quinone reductase), complex IV (cytochrome oxi-
dase) and complex V (ATPase) of the mitochondrial 
respiratory chain.2 The G13513A mutation in the 
mitochondrial ND5 gene was first reported in patients 
with mitochondrial encephalopathy with lactic ac-
idosis and stroke-like episodes (MELAS) in 1997.3 In 
further reports, this mutation was reported to be 
related to Leigh syndrome accompanied by Wolff-
Parkinson-White (WPW) syndrome and/or optic 
atrophy.2,4−7 Here, we present a female infant with 
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classical Leigh syndrome with onset at the age of 
11 months, accompanied by WPW syndrome and 
dilated cardiomyopathy (DCM).
2. Case Report
An 18-month-old girl was brought to our outpatient 
clinic because of developmental regression. She 
was the first child of non-consanguineous parents. 
She was born at term via vaginal delivery after an 
uneventful pregnancy. She had poor body weight 
gain and delayed gross motor development. She 
could sit up alone without support at 10 months 
old and walk holding on to furniture at 11 months 
old. After a period of fever, she developed bilateral 
exotropia and became unable to sit well. Over the 
following 6 months, there was no further deterio-
ration or improvement in motor achievement. She 
produced meaningful words at 11 months old and 
had gradual improvement in her language. At the age 
of 18 months, she was admitted to our hospital for 
evaluation.
On admission, her body weight was 8.1 kg (< 3rd 
percentile), and body length was 75.5 cm (3rd−10th 
percentile). She could say simple words such as 
“papa” and “mama”, but could not sit steadily by 
herself. Bilateral exotropia, ptosis and mild spastic-
ity of the lower limbs were found. Pale optic discs 
were detected by an ophthalmologist, but there 
was no obvious optic atrophy. Bilateral knee jerk 
was also exaggerated. Initial laboratory studies re-
vealed normal complete blood counts, liver aspar-
tase, blood urea nitrogen, creatinine and electrolytes. 
Serum lactate was elevated to 2.72 mmol/L (nor-
mal, < 2.2 mmol/L). Brain magnetic resonance im-
aging revealed multiple lesions over the brainstem, 
periaqueductal area and bilateral thalami, compat-
ible with a diagnosis of Leigh syndrome. Magnetic 
resonance spectroscopy of the basal ganglion also 
revealed a small lactate duplex. Cerebrospinal fluid 
lactate was also elevated to 2.8 mmol/L. Muscle bi-
opsy from the left quadriceps showed no ragged red 
fibers, and electron microscopy found no evidence 
of mitochondrial cytopathy.
WPW syndrome with left bundle branch block 
was revealed by delta waves on an electrocardio-
gram. Echocardiography revealed hypertrophic car-
diomyopathy (HCM) with borderline left ventricle 
contractility. The left ventricular ejection fraction 
(LVEF) was 61%. Attenuated wave V was noted on 
brainstem auditory evoked potentials, indicating 
significant brainstem involvement. Goggled visual 
evoked potential was absent. mtDNA G13513A muta-
tion was detected in blood and muscle specimens 
using restriction fragment length polymorphism 
(RFLP) analysis, while direct sequencing of mtDNA 
in blood and muscle specimens also revealed 
G13513A heteroplasmic change (Figure). Coenzyme 
Q10, thiamine, and carnitine were prescribed for 
the patient following diagnosis of Leigh syndrome. 
Propranolol was also given for WPW syndrome. 
She was discharged in a stable condition.
The patient experienced mild improvements in 
her language skills over the following months, but 
was still unable to sit well despite medication and 
rehabilitation. She was intubated twice for respi-
ratory infections and later required bilevel posi-
tive airway pressure (BiPAP) support at night. Her 
heart function also deteriorated rapidly. DCM was 
diagnosed 11 months later and her LVEF dropped to 
26%. Captopril, furosemide and carvedilol were given 
for heart failure. Her respiratory and cardiac func-
tions became stable, but BiPAP support was still 
needed at night. She remained exotropic, with no 
obvious visual response. She remained unable to sit 
steadily, despite regular rehabilitation, but no further 
regression in motor function was observed.
Figure Direct sequencing of mtDNA revealed G13513A heteroplasmic change.
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3. Discussion
The G13513A mutation of mtDNA was first described 
by Santorelli et al in 1997 in patients with MELAS.3 
The mutation results in an amino acid substitution 
in the ND5 subunit of complex I and can significantly 
interfere with the function of complex I.8 Mito-
chondrial complex I (NADH ubiquinone reductase) 
accepts electrons from NADH, transfers them to ubi-
quinone (coenzyme Q10) and uses the energy re-
leased to pump protons across the mitochondrial 
inner membrane. The ND5 subunit of complex I is a 
component of the hydrophobic protein fragment 
that contains around 15 transmembrane stretches, 
which are antiporter-like subunits probably involved 
in proton pumping activity.9 However, the real func-
tion of ND5 in complex I is currently still unclear.
The most common reported result of G13513A mu-
tation is Leigh or Leigh-like syndrome. There have 
been 14 reported cases of patients with Leigh or 
Leigh-like syndrome associated with mitochondrial 
G13513A mutation (Table).2,5−7 These patients most 
often present with initial psychomotor retarda-
tion, followed by psychomotor regression, between 
6 months and 5 years of age.
Our case also had severe heart involvement, in-
cluding WPW syndrome and DCM. Cardiac conduc-
tion abnormalities are also frequently seen in some 
mitochondrial diseases, such as Kearns-Sayre syn-
drome, MELAS, and some specific defects of fatty 
acid oxidation.10 It is significant that in the 15 re-
ported cases of Leigh syndrome with mtDNA G13513A 
mutation, six patients (40%) also presented with 
WPW syndrome. In contrast, the G13513A mutation 
has never been reported in patients with other mi-
tochondrial disease, such as MELAS or Leber’s he-
reditary optic neuropathy in association with WPW 
syndrome.11−13
Table Clinical characteristics of all reported cases with mitochondrial G13513A mutation






sex at onset*  involvement
1/F 19 mo BG, brainstem WPW Optic atrophy,  7
    ptosis, strabismus
2/M 9 mo Brainstem, thalamus WPW Ptosis 7
3/M 28 mo Brainstem, thalamus PSVT (−) 7
4/M 9 mo Brainstem ICRBBB Ptosis, strabismus 7
5/F 5 yr BG, brainstem, WPW, PSVT,  Ptosis 7
  cerebral lesion AV block
6/F 4 yr BG, brainstem (−) Optic atrophy,  7
    ptosis, strabismus
7/M 6 mo SN Transient HCM Opthalmoplegia 2
8/M 1 yr SN, dorsal medulla Severe HCM ND 2
 9 mo
9/M 1 yr SN, dorsal medulla ND Ptosis,  2
 9 mo   opthalmoplegia
10/M ND Superior colliculi,  ND Opthalmoplegia 5
  red nuclei
11/F 3 yr BG ND Optic atrophy,  5
    nystagmus
12/M Adult Midbrain, pons HCM Optic atrophy,  5
    exotropia
13/M 1 yr ND WPW Strabismus,  6
 6 mo   optic atrophy
14/F 9 yr ND WPW Optic atrophy,  6
    ptosis, nystagmus, 
    opthalmoplegia
15/F 11 mo BG, brainstem,  WPW, LBBB,  Ptosis, strabismus,
(our case)  thalamus DCM opthalmoplegia
*The onset age of symptoms other than developmental delay. BG = basal ganglion; WPW = Wolff-Parkinson-White syndrome; PSVT = 
paroxysmal supraventricular tachycardia; ICRBBB = incomplete right bundle branch block; AV = atrioventricular; SN = substantia 
nigra; HCM = hypertrophic cardiomyopathy; ND = no data; LBBB = left bundle branch block; DCM = dilated cardiomyopathy.
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There have been few studies on the pathogenic 
mechanisms of mitochondrial dysfunction in WPW 
syndrome. Abnormal mitochondria have been found 
in surgically resected pathways in WPW syndrome.14 
Mutation in the PRKAG2 gene, which encodes the 
γ2 regulatory subunit of AMP-activated protein ki-
nase, leads to familial WPW syndrome with auto-
somal dominant trait.15 The AMP-activated protein 
kinase has been described as a “cellular fuel 
gauge”,16 and the mutation may result in defects 
during cardiac morphogenesis, resulting in devel-
opment of an accessory pathway. Mitochondria also 
play an important role in cellular energy regulation, 
and mutations in their DNA might have similar ef-
fects to PRKAG2 mutations.
Cardiomyopathy is a common finding in complex I 
deficiency.4 Both DCM and HCM are frequently ac-
companied by altered levels of specific OXPHOS/
respiratory enzyme activities.10 Although HCM has 
also been reported in patients with G13513A muta-
tion in other series (Table, Patients 8 and 12),5,6 it 
may transform into DCM, as in the case presented 
here. There has been another record of a patient 
with the mitochondrial C3303T mutation who was 
reported to have progressed from HCM to DCM within 
1 year.17 Mitochondrial C3303T encodes the mito-
chondria tRNA for leucine, and its mutation may have 
resulted in the development of cardiomyopathy.18 
DCM is thought to occur during the later stages of 
severe oxidative stress,19 and because cardiomy-
opathy related to mitochondrial cytopathies may 
change in pattern, serial follow-up by echocardiog-
raphy is needed.
Patients with mitochondrial encephalomye-
lopathy usually have a high frequency of ophthal-
mic manifestations, including pigmentary retinal 
degen eration, external ophthalmoplegia, ptosis, 
and optic neuropathy.20 These can be the first signs 
of the disease, and develop long before central 
nervous system involvement becomes apparent.6 
In the 15 reported cases (Table), six patients (40%) 
also presented with optic atrophy. Complex I de-
ficiency is the usual cause of Leber’s hereditary 
optic neuropathy and dominant optic atrophy. The 
genes involved in these disorders regulate the 
bioenergetic efficiency of the mitochondrial res-
piratory chain, the buffering of reactive oxygen 
species overproduction, the machinery of fission/
fusion and the control of apoptosis.21 mtDNA 
G13513A mutation leads to complex I disorders, 
which may partially explain the high incidence of 
optic atrophy.
In summary, we have reported a patient who 
presented with the classical symptoms of Leigh 
syndrome, and WPW syndrome. mtDNA G13513A 
mutation was detected by RFLP and direct sequenc-
ing. In the literature review, WPW syndrome and 
optic atrophy were common findings associated with 
this mutation. The patient suffered from rapid de-
terioration in heart function over a 1-year period. 
We suggest that screening for mtDNA G13513A mu-
tation and complex I activity should be performed 
in patients with Leigh syndrome in association with 
WPW syndrome and/or optic atrophy. Serial heart 
function monitoring by echocardiography is also 
suggested for this group of patients.
References
1. Schmiedel J, Jackson S, Schafer J, Reichmann H. Mitochon-
drial cytopathies. J Neurol 2003;250:267−77.
2. Chol M, Lebon S, Benit P, et al. The mitochondrial DNA 
G13513A MELAS mutation in the NADH dehydrogenase 5 gene 
is a frequent cause of Leigh-like syndrome with isolated 
complex I deficiency. J Med Genet 2003;40:188−91.
3. Santorelli FM, Tanji K, Kulikova R, et al. Identification of a 
novel mutation in the mtDNA ND5 gene associated with 
MELAS. Biochem Biophys Res Commun 1997;238:326−8.
4. Bugiani M, Invernizzi F, Alberio S, et al. Clinical and molec-
ular findings in children with complex I deficiency. Biochim 
Biophys Acta 2004;1659:136−47.
5. Kirby DM, Boneh A, Chow CW, et al. Low mutant load of 
mitochondrial DNA G13513A mutation can cause Leigh’s 
disease. Ann Neurol 2003;54:473−8.
6. Ruiter EM, Siers MH, van den Elzen C, et al. The mitochon-
drial 13513G > A mutation is most frequent in Leigh syndrome 
combined with reduced complex I activity, optic atrophy 
and/or Wolff-Parkinson-White. Eur J Hum Genet 2007;15:
155−61.
7. Sudo A, Honzawa S, Nonaka I, Goto Y. Leigh syndrome caused 
by mitochondrial DNA G13513A mutation: frequency and 
clinical features in Japan. J Hum Genet 2004;49:92−6.
8. Blok MJ, Spruijt L, de Coo IF, Schoonderwoerd K, Hendrickx 
A, Smeets HJ. Mutations in the ND5 subunit of complex I of 
the mitochondrial DNA are a frequent cause of oxidative 
phosphorylation disease. J Med Genet 2007;44:e74.
9. Cardol P, Boutaffala L, Memmi S, Devreese B, Matagne RF, 
Remacle C. In Chlamydomonas, the loss of ND5 subunit 
prevents the assembly of whole mitochondrial complex I 
and leads to the formation of a low abundant 700 kDa sub-
complex. Biochim Biophys Acta 2008;1777:388−96.
10. Marin-Garcia J, Goldenthal MJ. Understanding the impact 
of mitochondrial defects in cardiovascular disease: a review. 
J Card Fail 2002;8:347−61.
11. Mashima Y, Kigasawa K, Hasegawa H, Tani M, Oguchi Y. High 
incidence of pre-excitation syndrome in Japanese families 
with Leber’s hereditary optic neuropathy. Clin Genet 1996;
50:535−7.
12. Nikoskelainen EK, Savontaus ML, Huoponen K, Antila K, 
Hartiala J. Pre-excitation syndrome in Leber’s hereditary 
optic neuropathy. Lancet 1994;344:857−8.
13. Sproule DM, Kaufmann P, Engelstad K, Starc TJ, Hordof AJ, 
De Vivo DC. Wolff-Parkinson-White syndrome in patients 
with MELAS. Arch Neurol 2007;64:1625−7.
14. Peters NS, Rowland E, Bennett JG, Green CR, Anderson RH, 
Severs NJ. The Wolff-Parkinson-White syndrome: the cel-
lular substrate for conduction in the accessory atrioven-
tricular pathway. Eur Heart J 1994;15:981−7.
15. Gollob MH, Green MS, Tang AS, et al. Identification of a 
gene responsible for familial Wolff-Parkinson-White syn-
drome. N Engl J Med 2001;344:1823−31.
mtDNA 13513 mutation in Leigh syndrome 149
16. Hardie DG, Carling D. The AMP-activated protein kinase—
fuel gauge of the mammalian cell? Eur J Biochem 1997;246:
259−73.
17. Yaplito-Lee J, Weintraub R, Jamsen K, Chow CW, Thorburn 
DR, Boneh A. Cardiac manifestations in oxidative phospho-
rylation disorders of childhood. J Pediatr 2007;150:407−11.
18. Silvestri G, Santorelli FM, Shanske S, et al. A new mtDNA 
mutation in the tRNA(Leu(UUR)) gene associated with mater-
nally inherited cardiomyopathy. Hum Mutat 1994;3:37−43.
19. Scaglia F, Towbin JA, Craigen WJ, et al. Clinical spectrum, 
morbidity, and mortality in 113 pediatric patients with 
mitochondrial disease. Pediatrics 2004;114:925−31.
20. Hayashi N, Geraghty MT, Green WR. Ocular histopathologic 
study of a patient with the T 8993-G point mutation in 
Leigh’s syndrome. Ophthalmology 2000;107:1397−402.
21. Carelli V, La Morgia C, Iommarini L, et al. Mitochondrial 
optic neuropathies: how two genomes may kill the same 
cell type? Biosci Rep 2007;27:173−84.
